Atrial Fibrillation Medication Management
For atrial fibrillation management, start with oral anticoagulation using DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) for patients with CHA2DS2-VA score ≥2, beta-blockers for rate control, and consider rhythm control with catheter ablation or antiarrhythmic drugs based on symptom burden. 1
Anticoagulation Strategy
Risk Assessment and Indications
Use the CHA2DS2-VA score (simplified from CHA2DS2-VASc, removing sex category) to assess stroke risk 1, 2:
- CHA2DS2-VA ≥2: Anticoagulation recommended
- CHA2DS2-VA = 1: Anticoagulation should be considered
- CHA2DS2-VA = 0: Low risk, anticoagulation not needed
Drug Selection
DOACs are preferred over warfarin for all eligible patients 1. The four DOACs have equivalent efficacy:
- Apixaban: 5 mg twice daily (2.5 mg twice daily if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL)
- Dabigatran: 150 mg twice daily (110 mg twice daily for age >80 or high bleeding risk)
- Edoxaban: 60 mg once daily (30 mg if CrCl 15-50 mL/min, weight ≤60 kg, or certain P-glycoprotein inhibitors)
- Rivaroxaban: 20 mg once daily (15 mg if CrCl 15-49 mL/min) 3
Exceptions where warfarin is required: mechanical heart valves and moderate-to-severe mitral stenosis 1. For warfarin, maintain INR 2.0-3.0 with time in therapeutic range >70% 1.
Critical Anticoagulation Principles
- Never combine antiplatelet agents with anticoagulation unless acute vascular event or interim procedural need 1
- Continue anticoagulation regardless of rhythm status—even if sinus rhythm is restored, continue based on thromboembolic risk 1
- Do not use bleeding risk scores to withhold anticoagulation; instead, manage modifiable bleeding risk factors 1
Rate Control
First-Line Agents
Beta-blockers are the preferred initial rate control agents for all patients 1:
For LVEF >40%, choose from:
- Beta-blockers (metoprolol, bisoprolol, carvedilol)
- Diltiazem (120-360 mg daily ER)
- Verapamil (180-480 mg daily ER)
- Digoxin (0.0625-0.25 mg daily) 1, 3
For LVEF ≤40%, use only:
- Beta-blockers
- Digoxin (avoid calcium channel blockers in heart failure with reduced ejection fraction) 1
Acute Rate Control
For hemodynamically stable patients requiring urgent rate control 3:
- Metoprolol: 2.5-5 mg IV bolus over 2 minutes, up to 3 doses
- Diltiazem: 0.25 mg/kg IV over 2 minutes (may repeat 0.35 mg/kg), then 5-15 mg/h infusion
- Esmolol: 500 μg/kg bolus, then 50-300 μg/kg/min infusion
Target heart rate: <110 bpm at rest 1
Rhythm Control
Cardioversion Approach
For hemodynamic instability: immediate electrical cardioversion 1
For stable patients with AF >24 hours duration:
- Provide 3 weeks of therapeutic anticoagulation before cardioversion (DOACs preferred, or INR ≥2.0 for warfarin) 1
- Alternative: Perform transesophageal echocardiography to exclude thrombus, enabling early cardioversion 1
- Continue anticoagulation for ≥4 weeks post-cardioversion and long-term based on CHA2DS2-VA score 1
Pharmacological Cardioversion
For patients without structural heart disease (no severe LVH, HFrEF, or CAD):
- Flecainide IV or Propafenone IV (Class I recommendation) 1
- Vernakalant IV (exclude recent ACS, HFrEF, severe aortic stenosis) 1
For patients with structural heart disease (LVH, HFrEF, CAD):
Long-Term Rhythm Control
Catheter ablation (pulmonary vein isolation) is now recommended as first-line therapy for paroxysmal AF in suitable patients, not just after antiarrhythmic drug failure 1, 2. This represents a major shift from previous guidelines.
Antiarrhythmic drugs remain options but have limited efficacy:
- Flecainide/Propafenone: For patients without structural heart disease
- Amiodarone: For patients with structural heart disease or HFrEF (100-200 mg daily maintenance after loading)
- Dronedarone: Alternative option but requires liver function monitoring 3, 4
- Dofetilide/Sotalol: Require QTc monitoring and hospitalization for initiation 3
Common Pitfalls to Avoid
Underdosing DOACs: Use full standard doses unless specific dose-reduction criteria are met—underdosing increases stroke risk without reducing bleeding 1
Stopping anticoagulation after successful cardioversion: Thromboembolic risk persists regardless of rhythm; continue based on CHA2DS2-VA score 1
Early cardioversion without anticoagulation: If AF duration >24 hours, either provide 3 weeks of anticoagulation or perform TEE first 1
Using calcium channel blockers in HFrEF: Diltiazem and verapamil are contraindicated when LVEF ≤40% 1, 3
Adding antiplatelet therapy for stroke prevention: This increases bleeding without additional stroke reduction 1
Ongoing Management
Reassess periodically for: